Chronic kidney disease

Proton-pump inhibitors increase risk of kidney damage

Use of proton-pump inhibitors increases the risk of long-term kidney damage, a study shows. …

Study shows value of community pharmacists screening patients for chronic kidney disease

Community pharmacists can play a key role in diagnosing patients with unrecognised chronic kidney disease, suggests new research published in the Canadian Pharmacists Journal.…

PPI use increases risk of chronic kidney disease by as much as 50%

Proton pump inhibitors — used to inhibit gastric acid secretion — are associated with a 20–50% increase in the risk of developing chronic kidney disease, according to new research.…

Chronic Kidney Disease – Mineral and Bone Disorder: pathophysiology and treatment

How the pathophysiological mechanisms behind development of Chronic Kidney Disease - Mineral and Bone Disorder can be managed, using appropriate therapeutic interventions to prevent complications.…

Absolute levels of risk are needed to make informed decisions for patients

Renal adverse effects of proton pump inhibitors (PPIs) were described in your research briefing ‘Proton pump inhibitors linked with chronic kidney disease’ ( Clinical Pharmacist 2015;7:217). Simply telling us that there was a 10% or 50% increase among …

Proton pump inhibitors linked with chronic kidney disease

A growing body of evidence has linked proton pump inhibitors with acute kidney injury and now new research has also found links with chronic kidney disease.…

New drug for diabetic kidney disease has promising results

In an international study, finerenone was effective at reducing protein in the urine without the rate of side effects of other drugs in the class.…

Dialysis: principles and treatment options

How to choose between haemodialysis and peritoneal dialysis when starting renal replacement therapy.…

Dialysis: management

How to identify and manage potential complications and challenges presented by haemodialysis and peritoneal dialysis.…

EMA recommends treatment for rare kidney condition

The European Medicines Agency has recommended the approval of tolvaptan for the treatment of a rare inherited disease, autosomal dominant polycystic kidney disease.…